Zhu Ren, Tian Ye
Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, Suzhou.
Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai.
Drug Des Devel Ther. 2017 Dec 6;11:3481-3489. doi: 10.2147/DDDT.S149620. eCollection 2017.
The aim of this study is to develop a novel RGD and TAT co-modified docetaxel (DTX)-loaded liposome (LP) by the emulsification-solvent evaporation method. The prepared LPs were found to be in the size of 100 nm-110 nm. The transmission electron microscope photomicrographs were smooth, sub-spherical in shape, and aggregated to form small clusters. The DTX cumulative release from TAT and RGD co-modified LPs was significantly higher than that from other LPs due to decreased diffusion distance. Results of cell uptake showed that surface modification could indicate when cell internalization was changed and more drugs entered the cells successfully. Surprisingly, TAT and RGD co-modified DTX-LPs demonstrated a superior antiproliferative effect on A549 cells with a possible mechanism that suppressed the multidrug resistance phenomenon and exhibited a clear synergistic effect. In antitumor study, our results indicated that the form of TAT and RGD co-modified LPs had a better antitumor effect in vivo than the other formulations.
本研究的目的是通过乳化溶剂蒸发法开发一种新型的RGD和TAT共修饰的载多西他赛(DTX)脂质体(LP)。所制备的脂质体大小在100 nm至110 nm之间。透射电子显微镜照片显示其表面光滑,呈亚球形,且聚集形成小簇。由于扩散距离减小,TAT和RGD共修饰脂质体中DTX的累积释放量显著高于其他脂质体。细胞摄取结果表明,表面修饰可表明细胞内化何时发生变化,并且更多药物成功进入细胞。令人惊讶的是,TAT和RGD共修饰的DTX脂质体对A549细胞表现出优异的抗增殖作用,其可能机制是抑制多药耐药现象并表现出明显的协同作用。在抗肿瘤研究中,我们的结果表明,TAT和RGD共修饰脂质体在体内比其他制剂具有更好的抗肿瘤效果。